FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.678,83 -106,72 (-0,18%)
MacroGenics, Inc. (MGNX)
Dopo ore:
| Chiusura precedente | 15,22 |
| Aperto | 15,64 |
| Denaro | 15,60 x 100 |
| Lettera | 15,70 x 100 |
| Min-Max giorno | 15,32 - 16,14 |
| Intervallo di 52 settimane | 4,29 - 21,88 |
| Volume | |
| Media Volume | 1.482.118 |
| Capitalizzazione | 980,323M |
| Beta (5 anni mensile) | 2,11 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,15 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 24,80 |
GlobeNewswireMacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
ROCKVILLE, MD, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc. (NASDAQ: GILD), nominated the first of two research programs, leveraging MacroGenics’ DART® and TRIDENT® platforms for generating bispecific antibodies. This nomination grants Gilead an exclusive option, upo
- GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: Citi’s 18th Annual BioPharma Conference (Boston). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Di
- GlobeNewswire
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data from TZIELD® (teplizumab-mzwv) type 1 diabetes study Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused
